Azathioprine
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Azathioprine
| |
| Systematic (IUPAC) name | |
| 6-(3-methyl-5-nitro-imidazol-4-yl)sulfanyl-7H-purine | |
| Identifiers | |
| CAS number | |
| ATC code | L04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C9H7N7O2S |
| Mol. mass | 277.264 g/mol |
| Pharmacokinetic data | |
| Bioavailability | Well absorbed |
| Metabolism | ? |
| Half life | 3hr |
| Excretion | renal, minimally |
| Therapeutic considerations | |
| Pregnancy cat. |
D |
| Legal status |
Approved Drug |
| Routes | oral |
|
WikiDoc Resources for Azathioprine | |
|
Articles | |
|---|---|
|
Most recent articles on Azathioprine Most cited articles on Azathioprine | |
|
Media | |
|
Powerpoint slides on Azathioprine | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Azathioprine at Clinical Trials.gov Clinical Trials on Azathioprine at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Azathioprine
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Azathioprine Discussion groups on Azathioprine Patient Handouts on Azathioprine Directions to Hospitals Treating Azathioprine Risk calculators and risk factors for Azathioprine
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Azathioprine | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Azathioprine is an immunosupressant used in organ transplantation, autoimmune disease such as rheumatoid arthritis or inflammatory bowel disease such as Crohn's disease and ulcerative colitis. It is a pro-drug, converted in the body to the active metabolites 6-mercaptopurine and 6-thioinosinic acid.
Azathioprine is produced by a number of generic manufacturers and as branded names (Azasan by Salix in the U.S., Imuran by GlaxoSmithKline in Canada and the U.S., Australia and UK and Azamun in Finland).
History
Azathioprine was first introduced into clinical practice by Sir Roy Calne, the British pioneer in transplantation. Following the work done by Sir Peter Medawar in discovering the immunological basis of rejection of transplanted tissues and organs, Calne introduced 6-mercaptopurine as an experimental immunosuppressant for kidney transplants. When azathioprine was discovered, he then introduced it as a less toxic replacement for 6-mercaptopurine. For many years, dual therapy with azathioprine and steroids was the standard anti-rejection regime, until cyclosporine was introduced into clinical practice (also by Calne) in 1978.
Mechanism of action
Azathioprine acts to inhibit purine synthesis necessary for the proliferation of cells, especially leukocytes and lymphocytes. It is an effective drug used alone in certain autoimmune diseases, or in combination with other immunosuppressants in organ transplantation. Side effects are uncommon, but include nausea, HA and rash. Because azathioprine suppresses the bone marrow, patients will be more susceptable to infection. Caution should be exercised when it is used in conjunction with purine analogues such as allopurinol. The enzyme thiopurine S-methyltransferase (TPMT) deactivates 6-mercaptopurine. Genetic polymorphisms of TPMT can lead to excessive drug toxicity, thus assay of serum TPMT may be useful to prevent this complication.[1]
Mycophenolate mofetil is increasingly being used in place of azathioprine in organ transplantation as it is associated with less bone marrow suppression, fewer opportunistic infections and a lower incidence of acute rejection.[1] However azathioprine certainly still has a major role.
Long term side effects
It is listed as a human carcinogen in the 11th Report on Carcinogens of the U.S. Department of Health and Human Services, although they note that the International Agency for Research on Cancer (IARC) considered some of the animal studies to be inconclusive because of limitations in the study design and inadequate reporting.[1] The risks involved seem to be related both to the duration and dosage used. People who have previously been treated with an alkylating agent may have an excessive risk of cancers if treated with azathioprine. Epidemiological studies have provided "sufficient" evidence of Azathioprine carcinogenicity in humans,[1] although the methodology of past studies and the possible underlying mechanisms are questioned.[1] The various diseases requiring transplantation, and thus azathioprine, may in themselves increase the risks of non-Hodgkin's lymphoma, squamous cell carcinomas of the skin, hepatobiliary carcinomas and mesenchymal tumours to which azathioprine may add additional risks. Those receiving azathioprine for rheumatoid arthritis may have a lesser risk than those following transplantation.[1]
Azathioprine is not thought to cause fetal malformation (teratogenesis) and any risk to the offspring of treated men is small.[1] A more recent product monograph produced by Glaxo Smith Kline and dated June 2005 does note that IMURAN® can cause fetal harm when given to a pregnant woman. Their document also states that the drug should not be given during pregnancy or in patients of reproductive potential without careful weighing of benefit versus the risks and should be avoided whenever possible in pregnant women. It goes on to say that when used in pregnancy the patient should be apprised of the potential hazard to the fetus. While stating that no adequate and well-controlled studies have taken place in humans, it notes that when given to animals in doses equivalent to human dosages teratogenesis was observed. Transplant patients already on this drug should not discontinue on becoming pregnant. This contrasts to the later developed drugs tacrolimus and myophenolate which are contra-indicated by the manufacturers during pregnancy.[1] As for all cytotoxic drugs, it is advised not to breastfeed whilst taking azathioprine.
Under FDA rules, this drug, like many others, excludes eligibility for blood donation.
References
External links
- Imuran® (GlaxoSmithKline Patient Information Leaflet)
- Azasan® (manufacturer's website)
- Medline Plus advice on Imuran ( A service of the National Institutes of Health)
- GSK Product Monograph for Imuran (for Canadian patients only)
nl:Azathioprinefi:Atsatiopriini
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
